



ASX/MEDIA RELEASE

29th May 2017

Results of Injunction Hearing on Share Buy-Back

Sydney, Australia; 29th May 2017 – Sirtex Medical Limited (ASX:SRX) today announces the Federal Court hearing relating to an injunction application filed by the Applicant, which has delayed commencement of the Company's \$30 million on-market share buy-back, was dismissed.

Accordingly, Sirtex intends to commence the buy-back following the ASCO Annual Meeting on 7th June 2017, as previously notified to the ASX on 10th April 2017.

About Sirtex Medical

Sirtex Medical Limited (ASX:SRX) is an Australian-based global healthcare business working to improve outcomes in people with cancer. Our current lead product is a targeted radiation therapy for liver cancer. Over 73,000 doses have been supplied to treat patients with liver cancer at 1,060 medical centres in over 40 countries. For more information please visit www.sirtex.com.

For further information, please contact:

Investor Enquiries:

Mr Darren Smith
CFO & Company Secretary
Sirtex Medical Limited
Phone: +61 (0) 2 9964 8400

Investor/Media Enquiries:

Dr Tom Duthy
Global Investor Relations Manager
Sirtex Medical Limited
Phone: +61 (0) 2 9964 8427
Email: tduthy@sirtex.com

Head Office

Level 33, 101 Miller Street
North Sydney, NSW 2060
Australia

Americas

300 Unicorn Park Drive
Woburn, MA 01801
United States

Europe, Middle East & Africa

Josef-Schumpeter-Allee 33
53227 Bonn
Germany

Asia Pacific

50 Science Park Road, #01-01
The Kendall Science Park II
Singapore 117406